Skip to content

Bioresorbable Intramedullary Nailing of Forearm Fractures

PMCF Study - Verification of Activa IM-Nail™ Safety and Clinical Performance

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04846543
Acronym
BRINFF
Enrollment
220
Registered
2021-04-15
Start date
2021-03-01
Completion date
2024-09-30
Last updated
2021-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Forearm Fracture

Brief summary

The Activa IM-Nail™ is used in the fixation of forearm fractures with cast to achieve a level of reduction and stabilisation that is appropriate to the age of the child. The post-market clinical follow-up study will be performed to identify the residual risk related to re-fracture and to determine its impact to the risk/benefit ratio of Activa IM-Nail™.

Detailed description

Residual risk related to re-fracture rate will be addressed by this PMCF study. The research question is, if the re-fracture risk with Activa IM-nail is in line with the other treatment methods, namely ESIN. Primary objective: will be to assess clinical outcome by determining re-fracture rate of all treated patients, difference of re-fracture rate depending on the fracture type determined by X-ray (e.g. greenstick vs. non-greenstick fracture), subject's age, BMI, surgical technique, immobilization time and bony union formation.

Interventions

OTHERMRI Scan

MRI scan

Sponsors

Bioretec Ltd.
CollaboratorINDUSTRY
Thomas Klestil
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
3 Years to 12 Years
Healthy volunteers
No

Inclusion criteria

* Diaphyseal forearm fractures (radius or ulna or both) * Patients from 3 years to under 13 years, but the age limits depend on the biological development of the child and in addition

Exclusion criteria

* multifragmentary fractures, metaphyseal and epiphyseal fractures * Situations where internal fixation is otherwise contraindicated, e.g., active or potential infection, or where a patient's cooperation cannot be guaranteed.

Design outcomes

Primary

MeasureTime frameDescription
Refracture rateFirst year after operationAssessment of refracture rate

Secondary

MeasureTime frameDescription
Absorption of implantOne and two years after operationMRI scans are performed to evaluate soft tissue reaction and biodegradability
Bony unionOne year after operationBony union depending on fracture type and immobilization time, return to sport
Monteggia lesion and equivalent2 years after operationSafety and performance of operative technique in Monteggia´s lesion
Cost effectiveness1 year after operationHTA assessment for different health care systems in Europe

Countries

Austria, Denmark, France, Germany, Hungary, Portugal, Switzerland

Contacts

Primary ContactChristoph Roeder, MD
christoph.roeder@moedling.lknoe.at+4322529004
Backup ContactThomas Klestil, MD
thomas.klestil@moedling.lknoe.at+4322529004

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026